ABSTRACT
OBJECTIVE: To study the pharmacokinetics and accumulation of deramciclane and its metabolite N-desmethylderamciclane after 60 mg twice daily doses for 4 weeks. METHODS: Sixteen healthy male subjects, age range of 20-29 years, participated in this randomized, double-blind, parallel-group, placebo-controlled study. Ten subjects first received a single 60 mg dose of deramciclane followed by 60 mg deramciclane b.i.d. between days 4 and 31. Six subjects received matching placebo in a similar manner. Pharmacokinetics of deramciclane and N-desmethylderamciclane were determined on days 1, 10, 17, 24 and 31. Plasma prolactin concentrations were measured before drug administration and 4 hours after on the same days. Safety was monitored using repeat laboratory determinations and ECG recordings. RESULTS: The mean (SD) AUC(0-infinity) of deramciclane was 1,251 (385) ng x h/ml after the first dose. The AUC(tau) calculated for the dosing interval was significantly higher at week 1 (p = 0.048) than the AUC(0-infinity) after the first dose but thereafter there was no further accumulation of deramciclane. The mean accumulation indices at weeks 1, 2, 3 and 4 varied between 2.3 and 2.7 with no tendency to increase over time. The mean apparent elimination half-life of deramciclane was 24.9 (3.5) hours after the first dose and 29.3 (9.3) hours after 4-week repeated dosing; this difference was not statistically significant. The accumulation index of N-desmethylderamciclane increased from week 1 to week 2 but remained stable thereafter. The treatment was well tolerated. Plasma prolactin levels were not influenced by deramciclane administration. CONCLUSIONS: Deramciclane administration, 60 mg twice daily for 4 weeks to healthy male volunteers, is well tolerated, and there is no evidence of continuous accumulation of the drug during maintenance treatment. Deramciclane at a dose of 60 mg b.i.d. does not antagonize dopamine receptors to a significant degree.
Subject(s)
Anti-Anxiety Agents/pharmacokinetics , Camphanes/pharmacokinetics , Adult , Anti-Anxiety Agents/administration & dosage , Anti-Anxiety Agents/adverse effects , Area Under Curve , Blood Pressure/drug effects , Camphanes/administration & dosage , Camphanes/adverse effects , Double-Blind Method , Drug Administration Schedule , Heart Rate/drug effects , Humans , Male , Prolactin/bloodABSTRACT
UNLABELLED: Deramciclane is a new putative non-benzodiazepine-type anxiolytic compound. It is a selective serotonin 5-HT(2A) and 5-HT(2C) receptor antagonist and has also inverse agonist properties. The aim of this study was to reveal the pharmacokinetics and tolerability of deramciclane during repeated oral dosing in healthy male volunteers. SUBJECTS, MATERIAL AND METHODS: A randomized double-blind, placebo-controlled design was used. The study had three consecutive groups that received first a single oral dose of 10, 30 and 60 mg of deramciclane followed by twice a day administration for seven days. The total number of subjects was 28. The pharmacokinetic parameters were calculated for a single dose and after repeated administration. Tolerability was assessed by monitoring safety laboratory variables, electrocardiogram, heart rate, blood pressure and adverse events. RESULTS: The steady-state was reached during the seven-day administration. The pharmacokinetics of deramciclane was dose-proportional at steady-state at each dose level. Deramciclane accumulated about three-fold during repeated administration. The relative bioavailability of deramciclane increased about 1.4-fold compared to that of a single dose at each dose level. The mean elimination half-life of deramciclane for 10, 30 and 60 mg doses prolonged from 24.3, 20.9 and 22.9 h after a single dose to 30.5, 25.6 and 28.7 h at steady-state, respectively. Only few adverse events were reported, all mild and transient in nature. The most frequently reported adverse drug reactions were tiredness and headache. There were no deramciclane-induced changes in the clinical chemistry or hematology variables, blood pressure, heart rate or in electrocardiogram. CONCLUSIONS: In conclusion, the pharmacokinetics of deramciclane is linear over the dose range of 10 - 60 mg at steady-state. The slight non-linearity within the dose levels during repeated administration of seven days was regarded as clinically irrelevant. Deramciclane was safe and well tolerated up to doses of 60 mg b.i.d. for seven days.
Subject(s)
Anti-Anxiety Agents/pharmacokinetics , Camphanes/pharmacokinetics , Serotonin Antagonists/pharmacokinetics , Administration, Oral , Adult , Anti-Anxiety Agents/administration & dosage , Anti-Anxiety Agents/adverse effects , Anti-Anxiety Agents/blood , Biological Availability , Blood Pressure/drug effects , Camphanes/administration & dosage , Camphanes/adverse effects , Camphanes/blood , Double-Blind Method , Electrocardiography/drug effects , Heart Rate/drug effects , Humans , Male , Serotonin Antagonists/administration & dosage , Serotonin Antagonists/adverse effects , Serotonin Antagonists/bloodABSTRACT
Site specific bioavailability and metabolism of levosimendan was studied in ten dogs by placing intestinal access port catheters in different parts of the gastrointestinal tract. 14C-labelled levosimendan (0.1 mg/kg) was administered intravenously, by gastric tube and directly through catheters that were placed in the duodenum, jejunum and ileum. Plasma samples were collected and radioactivity in the different organs and tissues was measured. The results of the present study showed that bioavailability of levosimendan was high varying from 71 to 86% after extravascular administration. Metabolite OR-1855 concentrations in the plasma were about 3-4 times higher after administration to the ileum compared to the other administration routes. It can be concluded that the bioavailability of levosimendan is not affected by site specific administration. The bacteria or enzymes responsible for the metabolism of levosimendan are located in the lower parts of the gastrointestinal tract.
Subject(s)
Cardiotonic Agents/pharmacokinetics , Hydrazones/pharmacokinetics , Pyridazines/pharmacokinetics , Animals , Biological Availability , Cardiotonic Agents/administration & dosage , Cardiotonic Agents/blood , Cardiotonic Agents/metabolism , Dogs , Drug Administration Routes , Female , Hydrazones/administration & dosage , Hydrazones/blood , Hydrazones/metabolism , Injections, Intravenous , Male , Pyridazines/administration & dosage , Pyridazines/blood , Pyridazines/metabolism , Simendan , Tissue DistributionABSTRACT
RATIONALE: Deramciclane fumarate is a new 5-HT2A and 5-HT2C receptor antagonist with putative anxiolytic effects. In the present study the binding of deramciclane to serotonin 5-HT2A receptors in frontal cortex of healthy male volunteers was studied using [11C]-N-methyl spiperone ([11C]-NMSP) and positron emission tomography. METHODS: The receptor occupancy percentage was assessed by the means of inhibition of [11C]-NMSP from the 5-HT2A receptors in the frontal cortex. Single oral doses of 20, 50 and 150 mg deramciclane were given to three subjects at each dose level (total n = 9). The receptor occupancy was measured before deramciclane and at 3 and 6 h post-dosing except at the 20 mg dose level where only the 3-h measurement was done. The occupancy percentage was calculated with the ratio method using cerebellum as a reference area. RESULTS: Deramciclane inhibited [11C]-NMSP binding dose and concentration dependently. However, deramasciclane inhibited maximally only 52% of the [11C]-NMSP binding in the frontal cortex, indicating a non-5-HT2A receptor binding component of this radioligand in frontal cortex. On average, specific [11C]-NMSP binding cerebellum ratios below 0.355 were not possible to achieve in this population. The 52% inhibition was regarded to represent near 100% 5-HT2A receptor occupancy. The 50 and 90% receptor occupancies were reached at deramciclane plasma concentrations of 21 ng/ml and 70 ng/ml, respectively. CONCLUSIONS: Deramciclane penetrates the blood-brain barrier in humans. Deramciclane binds to the 5-HT2A receptors in the frontal cortex in a saturable manner in vivo. Consequently, the increase in deramciclane concentration in plasma above 70 ng/ml will not result in major increase in the 5-HT2A receptor occupancy in the brain.
Subject(s)
Camphanes/metabolism , Cerebral Cortex/chemistry , Receptors, Serotonin/metabolism , Serotonin Antagonists/metabolism , Administration, Oral , Adult , Animals , Camphanes/administration & dosage , Camphanes/blood , Dopamine Antagonists/metabolism , Dose-Response Relationship, Drug , Humans , Male , Receptors, Serotonin, 5-HT1 , Risperidone/metabolism , Serotonin Antagonists/administration & dosage , Serotonin Antagonists/blood , Tomography, Emission-ComputedABSTRACT
The pharmacokinetics and tolerability of a new putative non-benzodiazepine type anxiolytic compound deramciclane was studied in two consecutive studies. An open dose-escalation design was used to study doses from 0.2 to 50 mg in 18 healthy male volunteers. In the second study doses from 50 to 150 mg were investigated in 14 healthy males in a double-blind, placebo-controlled, dose escalation study. Deramciclane was rapidly absorbed from the GI-tract and T(max) was 2-4 h. The elimination half-life increased from about 20 h to about 32 h with the increasing dose. Nevertheless, the AUC(0-infinity) values increased linearly within the studies over the dose ranges of 3-50 and 50-150 mg. However, the increase was more than the ratio of the dose over the total dose range of 3-150 mg. Therefore, non-linear pharmacokinetics of deramciclane at high doses cannot be excluded. N-desmethyl deramciclane, which is the active metabolite of deramciclane, was determined in plasma. C(max) was reached at about 6 h. The AUC(0-48 h) for the N-desmethyl metabolite was about one third of the AUC(0-infinity) of the parent compound and the ratio remained constant at each dose level. Deramciclane was safe, and was well tolerated at each dose level.
Subject(s)
Camphanes/adverse effects , Camphanes/pharmacokinetics , Serotonin Antagonists/adverse effects , Serotonin Antagonists/pharmacokinetics , Adult , Area Under Curve , Biotransformation , Blood Pressure/drug effects , Camphanes/administration & dosage , Chromatography, Liquid , Double-Blind Method , Heart Rate/drug effects , Humans , Male , Mass Spectrometry , Serotonin Antagonists/administration & dosageABSTRACT
The pharmacokinetics of a new serotonin 5-HT2 antagonist, deramciclane, was studied. Single oral doses of 1, 3, 6 and 10 mg kg(-1) and intravenous doses of 1, 3 and 6 mg kg(-1) were administered in beagle dogs. Moreover, the steady state pharmacokinetics of 1, 3 and 6 mg kg(-1) doses were studied. Deramciclane was rapidly and completely absorbed from the gastrointestinal tract. Due to a moderate first-pass metabolism the absolute bioavailability was only 45-61%. Deramciclane had a large volume of distribution (32-37 L kg(-1)) because of its lipophilic nature. Deramciclane was extensively metabolized after intravenous injection and only trace amounts of intact drug is excreted in the urine. The total body clearance decreased (from 32 to 17 L h(-1)) as the dose increased. It is suggested that the metabolic capacity was not sufficient to eliminate deramciclane in a linear manner with increasing dose. Therefore, deramciclane exhibited nonlinear pharmacokinetics as the AUC(0-infinity) increased disproportionally to the dose after both intravenous and oral dosing. Formation of the active metabolite, N-desmethyl deramciclane, was also nonlinear (p = 0.0002). At steady state deramciclane accumulated less than 2-fold during repeated administration.
Subject(s)
Anti-Anxiety Agents/pharmacokinetics , Camphanes/pharmacokinetics , Administration, Oral , Animals , Anti-Anxiety Agents/administration & dosage , Area Under Curve , Biotransformation , Camphanes/administration & dosage , Dealkylation , Dogs , Half-Life , Injections, IntravenousABSTRACT
We have studied the dog model for predicting the oral absorption of deramciclane, a novel anxiolytic compound, as a model acid-labile drug. The absorption profile of deramciclane was studied in man and beagle dogs after administration of conventional capsules and enteric coated tablets. Absorption in dogs pretreated with pentagastrin or saline was also studied after administration of conventional capsules. The in-vitro stability of deramciclane was determined over the pH range 1.2-6.0. The rate of degradation of deramciclane increased ten-fold as the pH was reduced from 2.1 to 1.2 (t 1/2 beta (elimination half-life) 9 h and 39 min, respectively). Deramciclane was stable at pH > or = 3. The two formulations were bioequivalent in dogs and there were no significant differences between pharmacokinetic parameters measured for dogs pretreated with pentagastrin or saline. In man the mean relative bioavailability and Cmax (peak plasma concentration) for the conventional capsules were approximately 75% and 83% of those for the enteric coated tablets (P = 0.0004 and P = 0.0031, respectively). This was probably because of degradation of deramciclane at lower pH of man's stomach compared with that of the dog. Pentagastrin was probably unsuccessful in reducing gastric pH and thus no change in absorption was observed. It is concluded that the absorption of deramciclane, and possibly other acid-labile drugs, cannot be predicted by use of the dog model.
Subject(s)
Anti-Anxiety Agents/pharmacokinetics , Camphanes/pharmacokinetics , Absorption , Adult , Animals , Anti-Anxiety Agents/blood , Camphanes/blood , Cross-Over Studies , Dogs , Drug Interactions , Humans , Hydrogen-Ion Concentration , Male , Metabolic Clearance Rate , Pentagastrin/pharmacologyABSTRACT
Scanora (Soredex, Orion Corporation, Helsinki, Finland) is a multimodal radiography system which utilizes the principles of narrow beam radiography and spiral tomography. The system includes an integrated multifunction X-ray unit, a coordinate system for object localization and a wide selection of dental and maxillofacial imaging problems. All imaging procedures are computer controlled and executed automatically. Clinical experience and preliminary results show that the multimodal imaging system has great potential in the detection of pathological conditions of the maxillofacial region.
Subject(s)
Radiography, Panoramic/methods , Tomography, X-Ray Computed , HumansABSTRACT
The use of the modulation-transfer function in defining the layer thickness in rotational panoramic radiography is discussed. This method is compared with other methods and is shown to be a more accurate means for describing the layer.
Subject(s)
Radiography, Panoramic/methods , Models, Theoretical , Radiographic Image Enhancement , Radiography, Dental , Radiography, Panoramic/instrumentation , Rotation , X-Ray FilmABSTRACT
The use of the modulation transfer function in rotational panoramic radiography is described. The separate and combined effects of the various system components are discussed.